Morepen Laboratories Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/y78jzukm1xf3z91zhms9wir5.pdf

Key Takeaways


The Strategic Pivot: B2B to B2C

Sushil Suri: "There is a complete shift in the overall strategy of the company. And as we all know that traditionally Morepen had been an API player. So we have been working on a B2B business model... It's only last couple of years that we have been able to get good headway in the consumer business also."

Medical Devices: The Installed-Base Flywheel

Sushil Suri: "Our selling price in India at retail level is $2, $3, $5. So there the starting point is between $15 to $20. So it's much higher."

API: Strategic Degrowth, Not Customer Loss

Sushil Suri: "Being a market leader if Morepen reduces price for example, Montelukast as an example normal running price of Montelukast some years ago was like INR35,000. During COVID time, it reached up to INR58,000. From INR58,000, it came down to back to INR32,000, INR30,000. And if someone asking me INR26,000, I can't give it."

Margins: A Record Run, With a Roadmap

Sushil Suri: "It is for the first time in the history of last 40 years that collective four quarters, we are getting a INR50 crores plus EBITDA on an average."

Capex, Facilities & The 2030 Vision

Sushil Suri: "I would say a lot cooking in. So I have to keep quiet on certain things."

Pushback & Unanswered Questions


Guidance & Commitments

CommitmentSpecificsTimeline
QIP capex cycle completionAll expansion projects from QIP funds finished18–24 months, by end of FY26
Baddi facility order bookingsValidation and filings complete, orders begin12–18 months
Medical devices CAGR25–26% growthSustained over medium term
Overall company CAGR~20%To FY30
Revenue target₹5,000 crores toplineBy 2030
EBITDA margin target15%In next three years
EBITDA margin target17–18%In next five years
Medical device revenue share40% of total revenue (40:60 devices:pharma)By 2030
API capacity expansion400 KL to 600 KL; 50 KL done, balance this quarterVolume upside from next quarter onward
Medical device demergerRegulatory process complete, separate subsidiary operationalBetween this quarter and next quarter
Medical devices FY25 revenue₹545–550 croresFY25
Strategic direction clarityClear direction on fundraising and value unlockingNext two quarters
Medical representative expansionFrom ~200 to 1,000Next five years
Branded finished-dosage networkPan-India expansionNext three years

Key Metrics

MetricQ2 FY25
Revenue₹443 cr, +4% YoY
H1 Revenue₹901 cr, +9% YoY
EBITDA₹49 cr, +33% YoY
H1 EBITDA₹104 cr, +59% YoY
EBITDA margin11.55% in H1, up from 10.13% in FY24
Profit after tax₹35 cr, +64% YoY
H1 PAT₹71 cr
Quarterly EPS₹0.65
TTM EPS₹2.53
Pharma segment H1 revenue₹630 cr, +9% YoY
Medical devices H1 revenue₹271 cr, flat YoY
Export growth in H1+21% YoY, to ₹337 cr
Installed glucometer base1.3 cr meters, up from 1.06 cr a year ago
Strips sold in H122.1 cr strips, +10% YoY
Strips per meter~165, up from ~150 a year ago
BP monitors sold in H1~3 lakh units, vs 3.1 lakh a year ago
New product contribution13.6% of pharma revenue in H1, up from ~10% a year ago
QIP balance remaining₹137 cr as of 30 Sep 2024